Two other major product introductions are anticipated in 2011: generic Concerta for ADHD and generic Solodyn for bacterial infections, currently with combined sales of $1.8 billion. My target for the stock is $35-$40 in one to two years. IPXL is also the possible target of an acquirer. At the time of publication, Michael Shulman owned shares of CERS and CRIS. Michael Shulman is the editor of Short-Side Trader. >To see these stocks in action, visit the 5 Bargain Biotech Stocks portfolio on Stockpickr.